In vitro anticancer and anti-inflammatory potential of Tian immune booster
| dc.contributor.author | Hailume, Moses Kaufiweni | |
| dc.date.accessioned | 2021-07-01T06:23:31Z | |
| dc.date.available | 2021-07-01T06:23:31Z | |
| dc.date.issued | 2021 | |
| dc.description | A mini thesis submitted in partial fulfillment of the requirements for the Degree of Master of Science (Industrial Biochemistry) | en_US |
| dc.description.abstract | Tian Immune Booster (TIB) is a Chinese herbal product made up of more than 30 different Chinese herbs and formulated in sugar-coated tablets. TIB is currently approved for use in China, Kenya and Zambia to manage liver and kidney diseases as well as HIV and cervical cancer. The use of TIB to manage diseases is currently based on traditional knowledge and clinical evidence, but scientific validation for this use is not available. Chronic inflammation is one of the contributing factors to the development of different diseases. The current study was aimed at investigating the in vitro anticancer and anti-inflammatory potential of TIB extracts. Anticancer and anti-inflammatory data from the present study may provide more insight into biological activities of TIB in terms of the potential to treat cancer and protection against inflammation respectively. The anticancer effects of TIB towards human cervical cancer (HeLa) and human malignant melanoma cell lines was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay at extract concentrations between 1.56 and 100 μg/mL. The albumin denaturation assay was used to evaluate the anti-inflammatory potential of TIB at concentrations between 3.12 and 200 μg/mL. The anticancer and anti-inflammatory potential of TIB was tested for single and combined extracts. No anticancer activity was observed with TIB towards HeLa and melanoma cells, with IC50 values ≥ 100 μg/mL for all extracts. TIB exhibited good anti-inflammatory activity, with IC50 values ranging from 14.53 ± 0.87 to 163.84 ± 10.59 μg/mL for single extracts and from 12.30 ± 0.29 to 44.85 ± 2.77 μg/mL for combined extracts. Minimal anticancer activity may be an indication that TIB does not directly kill cancer cells. Good anti-inflammatory activity revealed by this study support the traditional use of TIB. In future, in vivo anticancer and anti-inflammatory studies on TIB may be considered. | en_US |
| dc.identifier.uri | http://hdl.handle.net/11070/2951 | |
| dc.language.iso | en | en_US |
| dc.publisher | University of Namibia | en_US |
| dc.subject | Anti-inflammatory | en_US |
| dc.subject | Albumin denaturation | en_US |
| dc.subject | Anticancer | en_US |
| dc.title | In vitro anticancer and anti-inflammatory potential of Tian immune booster | en_US |
| dc.type | Thesis | en_US |